How AOC Will Change The World
In today’s Daily Journal, Porter tells readers everything they need to know about the latest medical breakthrough and how to make millions of dollars investing in it over the next decade.
Tech Frontiers
It Only Takes One Biotech Bull Market To Make You Rich… And It’s Here Now
Despite the rally in biotech we’ve seen this year, the opportunity today is now even better than it was when Erez Kalir launched his biotech newsletter in January of 2024. Remember, Porter writes today, It only takes one biotech bull market to make you rich.
Find A Different Game
If you want to succeed in investing – or in any field where competition is fierce – take a page from this investor’s book… and play the game differently than everyone else. Erez Kalir explains how.
Sell Alert: Half Position Of Prime Medicine
Shares of the Tech Frontiers July recommendation, Prime Medicine (Nasdaq: PRME), are trading at around $6.37 today, a gain of over 100% from our entry price of $3.07 three months ago. As a result, we recommend selling half your position. Prime is making terrific progress advancing its gene-editing platform and we have many reasons for
Hold Shares Of Fortress Biotech
Last week, Fortress Biotech (Nasdaq: FBIO) issued a press release disclosing that the Food And Drug Administration (“FDA”) had issued a Complete Response Letter (“CRL”) for CUTX-101, Fortress’s new drug to treat Menkes disease. A CRL is the FDA’s way of communicating it has decided against approving a new drug application in its current form.
When Rates Drop, These Stocks Soar
The potential for a new biotech bull market means there has never been a better time to become a Biotech Frontiers subscriber. But that’s not the only reason to consider joining Erez Kalir’s service today… Read on to learn more!